**Star News, on December 15, 2023, OPUMAI (688293) announced that Goldman Sachs Yan Tianyi Jenny Du investigated our company on December 12, 2023.
The details are as follows:
Q: Is it cheaper for customers to change the culture medium to our main test?
A: In the field of protein antibody drugs, the primary consideration is performance, and ** is not the primary consideration for customers.
Q: The current competitive landscape of the culture media industry?
A: At present, the three major imported brands still dominate the situation, especially in the field of protein antibody drugs, imported brands occupy 80% of the market share, and the company is currently the No. 1 domestic manufacturer.
Q: If the customer changes to our culture medium, how much can we help the customer express the volume??
Answer: We believe that doubling the expression volume is the minimum requirement, and it depends on the customer's requirements for various indicators, and the expression volume is too high for the downstream purification requirements, which still depends on the customer.
Q: What is the recruitment situation of the company?
A:;According to the needs of business progress, we will not blindly expand personnel. The sales staff are mainly recruited by the community, and the research and development is mainly recruited by the school.
The main business of OPUMAI (688293) is engaged in cell culture products and services.
According to the third quarter report of 2023, the company's main revenue is 17.2 billion yuan, down 2305%；Net profit attributable to the parent company is 4318280,000 yuan, a year-on-year decrease of 4803%；Deduct non-net profit of 3169860,000 yuan, a year-on-year decrease of 5686%；Among them, in the third quarter of 2023, the company's single-quarter main revenue was 5044140,000 yuan, a year-on-year decrease of 3397%；The net profit attributable to the parent company in a single quarter was 52970,000 yuan, a year-on-year decrease of 8219%；The non-net profit deducted in a single quarter was 207790,000 yuan, a year-on-year decrease of 9172%；The debt ratio is 648%, investment income 505220,000 yuan, financial expenses - 1804470,000 yuan, gross profit margin of 5883%。
A total of 9 institutions have rated the stock in the last 90 days, with 6 ratings ** and 3 overweight ratingsThe average institutional price target over the last 90 days is 7439。
Here's the detailed profit** information:
Margin data shows that the stock has a net financing outflow of 665 in the past three months730,000, the financing balance decreased;The net inflow of securities lending was 867250,000, the balance of securities lending increased.
The above content is compiled by **Star based on public information, generated by algorithms, and has nothing to do with the position of this site. **Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of the information (including but not limited to text, **audio, data and charts), if there is any problem, please contact us. This article is a compilation of data and does not constitute any investment advice for you, investment is risky, please make a cautious decision.